Your browser doesn't support javascript.
loading
Clinicopathological characterization of next-generation sequencing detected mutations in lung cancers-a single-center experience.
Walter, Julia; Tufman, Amanda; Kumbrink, Jörg; Neumann, Jens; Kahnert, Kathrin; Sellmer, Laura; Jung, Andreas; Behr, Jürgen; Kauffmann-Guerrero, Diego.
Afiliación
  • Walter J; Department of Medicine V, University Hospital, LMU Munich, Munich, Germany.
  • Tufman A; Comprehensive Pneumology Center Munich (CPC-M), Member of the German Center for Lung Research (DZL), Munich, Germany.
  • Kumbrink J; Department of Medicine V, University Hospital, LMU Munich, Munich, Germany.
  • Neumann J; Comprehensive Pneumology Center Munich (CPC-M), Member of the German Center for Lung Research (DZL), Munich, Germany.
  • Kahnert K; Institute of Pathology, Faculty of Medicine, Ludwig-Maximilians Universität (LMU) Munich, Munich, Germany.
  • Sellmer L; Institute of Pathology, Faculty of Medicine, Ludwig-Maximilians Universität (LMU) Munich, Munich, Germany.
  • Jung A; Department of Medicine V, University Hospital, LMU Munich, Munich, Germany.
  • Behr J; Comprehensive Pneumology Center Munich (CPC-M), Member of the German Center for Lung Research (DZL), Munich, Germany.
  • Kauffmann-Guerrero D; Department of Medicine V, University Hospital, LMU Munich, Munich, Germany.
Transl Lung Cancer Res ; 13(4): 799-810, 2024 Apr 29.
Article en En | MEDLINE | ID: mdl-38736491
ABSTRACT

Background:

Despite many advances in molecular procedures many lung cancer patients do not receive full panel testing. This can limit the comprehensive understanding of their disease and potentially hinder personalized treatment options.

Methods:

In this retrospective analysis, we used results from next-generation sequencing (NGS) testing of 154 patients with adenocarcinoma (AC) or squamous cell carcinoma (SCC) of the lung treated at the University Hospital, Ludwig-Maximilians Universität (LMU) Munich between 2018 and 2021. We compared different clinicopathological features and patients' baseline characteristics with results of NGS testing. We used t-test and analysis of variance (ANOVA) to compare metric- and χ2-test and Fisher's exact test to compare categorical variables.

Results:

NGS testing found mutations in 107 (69.5%) patients; 44 patients (28.6%) had more than one mutation. The majority (79.2%) of patients had AC and 64.9% were metastasized at diagnosis. Patients with detected mutations had significantly higher PD-L1 expression than those without mutations (36.4% vs. 19.2%, P=0.005). Mean PD-L1 expression also differed between different mutations ranging from 24.0% in EGFR to 56.8% in patients with MET alterations, and increased with the number of different mutations (P=0.07). EGFR mutations were significantly more common in females compared to males (22.9% vs. 9.5%, P=0.04) and PIK3CA mutations significantly more common in SCC (21.9% vs. 2.5%, P=0.004). We found 23 different mutations in AC and 13 different gene mutations in SCC.

Conclusions:

Mutation profiles differed by histological type and metastases status and were significantly associated with PD-L1 expression. In the context of limited resources, our results may help prioritize patient for testing when tissue material and funding is limited.
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Transl Lung Cancer Res Año: 2024 Tipo del documento: Article País de afiliación: Alemania

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Transl Lung Cancer Res Año: 2024 Tipo del documento: Article País de afiliación: Alemania